Abstracts tagged "colchicine and familial Mediterranean fever"

Abstract Number: 375 • 2017 ACR/ARHP Annual Meeting
Controlled Discontinuation of Colchicine Therapy in Familial Mediterranean Fever Patients with Single MEFV Mutation
Yonatan Butbul Aviel¹, Shafe Fahoum² and Riva Brik³, ¹Department of Pediatrics B Pediatric Rheumatology Service, Ruth Rappaport Children's Hospital, Rambam Medical Center, Haifa, Israel, Haifa, Israel, ²Department of Pediatrics B,, , Ruth Children's Hospital, Rambam Medical Center, Haifa, Israel, Pediatric Rheumatology Service, .Rappaport Faculty of Medicine, Technion-lsrael Institute of Technology, Haifa, Israel, ³Pediatrics, Rambam Medical Center, Haifa, Israel
Background/Purpose: Familial Mediterranean fever (FMF) traditionally has been considered an autosomal recessive disease; however, the diagnosis remains predominantly clinical, since mutations cannot always be identified…
Abstract Number: 2108 • 2017 ACR/ARHP Annual Meeting
Colchicine Treatment May be Protective Against Ventricular Arrhythmias in FMF Patients
Aslı Gozek Ocal¹, Lutfi Ocal² and Mehmet Engin Tezcan³, ¹Internal Medicine, University of Medical Sciences Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey, ²Cardiology, University of Medical Sciences Kosuyolu Kartal Heart Training and Research Hospital, Istanbul, Turkey, ³Rheumatology, University of Medical Sciences Kartal Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey
Background/Purpose: Familial Mediterranean fever (FMF) is an autoinflammatory disease. Colchicine is used in FMF patients for preventing attacks and amyloidosis. There were conflicting reports as…
Abstract Number: 262 • 2015 ACR/ARHP Annual Meeting
Canakinumab Therapy in Patients with Familial Mediterranean Fever
Serdal Ugurlu¹, Emire Seyahi², Gulen Hatemi², Aysa Hacioglu¹, Humeyra Ozcan¹, Fatma Nihan Akkoc¹ and Huri Ozdogan², ¹Rheumatology, Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: It has been reported that Canakinumab reduced the frequency of attacks in patients with Familial Mediterranean Fever (FMF) resistant to colchicine with no apparent…
Abstract Number: 1230 • 2014 ACR/ARHP Annual Meeting
Efficacy of Interleukin-1 Targeting Drugs in Familial Mediterranean Fever Patients
Pinar Cetin¹, Ismail Sari¹, Betul Sozeri², Ozlem Cam², Merih Birlik¹, Fatos Onen¹, Nurullah Akkoc¹ and Servet Akar¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Pediatrics, Ege University School of Medicine, Izmir, Turkey
Background/Purpose Familial Mediterranean fever (FMF) is an autosomal-recessive autoinflammatory disorder characterized by recurrent episodes of fever accompanied by sterile peritonitis. The most devastating complication of…
Abstract Number: 1208 • 2013 ACR/ARHP Annual Meeting
Canakinumab In Patients With FMF
Serdal Ugurlu¹, Emire Seyahi¹, Gulen Hatemi², Ayse Hacioglu² and Huri Ozdogan², ¹Division of Rheumatology,Department of Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, ²Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey
Background/Purpose: In a recent pilot study, it was reported that Canakinumab reduced the frequency of attacks in 9 patients with Familial Mediterranean Fever (FMF) resistant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].